Key Findings
- Transcriptomic analysis of 49,144 tumors profiled by Caris identified an HGNEC-like subset of NSCLC with poor survival, immune
suppression, and enrichment of targetable neuroendocrine-associated biomarkers. - In a longitudinal paired tumor analysis of 1,343 patients from the Caris real-world clinico-genomic cohort, post-treatment decreases in chromosome Y score were linked to worse survival across multiple cancer types, supporting further investigation of chromosome Y loss as a prognostic biomarker.
- This study highlights how comprehensive molecular profiling can uncover clinically relevant molecular subgroups, prognostic biomarkers, and therapeutic targets across diverse tumor types, supporting more precise biomarkerdriven research and treatment strategies.